Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
← catalyst calendarSponsored by CVRx, Inc. (industry) · CVRX — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
435actual
Sites
46
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Participant follow-up through 12 months post-Barostim Implant sufficient for data collection and analysis purposes.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-26 | actual | When the study began enrolling |
| Primary completion | 2026-05-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2020-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Heart Failure
Intervention
- Device: Barostim™ System
Primary outcome
what the primary-completion date above is the date OFThe primary objective of this post-market registry is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that were recently implanted with the Barostim System.
measured 36 months post-implant
Permalink · CVRX's whole pipeline · Catalyst calendar · Every registered study · What changed